In this episode of RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers, host Amanda Mixon, PA-C, is joined by Audrey Gibson, PA-C, for part two of their special RhAPP Up series covering key psoriatic arthritis updates from the 2026 EULAR Congress.

They discuss new long-term data highlighting the durability of response with emerging therapies in psoriatic arthritis, including how patients who respond early may be able to maintain disease control over several years. The conversation focuses on what sustained efficacy means for real-world treatment decisions and long-term disease management.

The episode also reviews subgroup data from a phase 3 study of an IL-23–targeting therapy, showing consistent improvements in joint symptoms and inhibition of structural damage progression across a range of patient types. The discussion highlights the importance of early inflammation control and its role in reducing long-term joint damage.

Whether you're a rheumatology provider, advanced practice provider (APP), or other healthcare professional, this episode offers practical insights into long-term treatment outcomes, emerging biologic therapies, and key factors that may influence therapy selection in psoriatic arthritis care.

Stay tuned for part three of the RhAPP Up series and visit the Content Rheum to stay up to date with the latest clinical insights in rheumatologic care.